Approved HIV Drugs
Approved HIV Drugs
ICAAC 2014: Stribild Works Well Regardless of Age, Sex, or Race/Ethnicity
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 23 September 2014 00:00
- Written by Liz Highleyman
The elvitegravir-based Stribild single-tablet regimen demonstrated good long-term efficacy and tolerability -- including fewer neuropsychiatric side effects than Atripla -- with consistent results across demographic subgroups, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC. Other studies showed that Stribild is a good option for black patients either initiating or switching antiretroviral therapy (ART).
Maraviroc Dose May Be Too Low for Many African-American People with HIV
- Details
- Category: Approved HIV Drugs
- Published on Monday, 08 September 2014 00:00
- Written by Johns Hopkins
A standard dose of the CCR5 antagonist maraviroc (Selzentry) may not be effective for many black people with HIV due to a genetic variation which increases production of a cytochrome P450 protein that speeds up processing of the drug, according to a study published in the August 12 advance edition of Drug Metabolism and Disposition.
AIDS 2014: Switching ART with Suppressed Viral Load Linked to Treatment Failure
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 29 July 2014 00:00
- Written by Liz Highleyman
People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20thInternational AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as adherence difficulties or treatment changes due to pregnancy.
AIDS 2014: Single-tablet HIV Regimens Not Necessarily More Durable
- Details
- Category: Approved HIV Drugs
- Published on Friday, 22 August 2014 00:00
- Written by Liz Highleyman
Antiretroviral therapy (ART) regimens consisting of 1 pill taken once-daily -- known as single-tablet regimens -- were not associated with a longer time to treatment discontinuation when compared to some other modern, well-tolerated regimens that involve more pills or twice-daily dosing, according to a study presented at the 20th International AIDS Conference last month in Melbourne.
AIDS 2014: Dolutegravir Demonstrates Good Efficacy Despite Resistance
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 29 July 2014 00:00
- Written by Liz Highleyman
Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who were resistant to NRTIs. Among people starting treatment for the first time, no resistance was detected through 96 weeks, according to study findings presented at the 20th International AIDS Conference last week in Melbourne.
Web Design and Development by